

Table S1 Reported cases of PACC received anti-tumor drug

Case No.	DOI (ref.)	Author	Reported year	Age (years)	Gender (M/F)	Altered gene	Reasons for chemotherapy	First line chemotherapy	Effect	Clinical course
1	10.1007/s10689-024-00390-3 (11)	Matsubayashi	2024	73	M	<i>BRCA2</i>	Liver metastasis in 13 months after surgery	olaparib	PR	N/A
2	10.1007/s00432-024-05841-z (12)	Merz	2024	69	M	<i>MLH1/MSI</i> -high	Locally advanced	mFFX	SD	SD with mFFX in 6 cycles. Sent for GnP (PD). PR with pembrolizumab. Sent for conversion surgery
3	10.1002/cnr2.70007 (13)	Kubo	2024	53	M	<i>BRCA1</i>	Liver metastasis after surgery	GnP	PD	PR with mFFX in 19 cycles. Switch to olaparib but PD in 4 months. PD with mFFX. PD with GEM
4	10.1007/s12328-024-01981-4 (4)	Urabe	2024	80	M	<i>BRCA2</i>	Relapse in remnant pancreas after surgery	GnP	PD	PD with S1 in 8 months. Radiation therapy. PD with S1 in 5 months. PR with mFFX (continued a year and 3 months). Switch to olaparib (maintained PR in a year). Survival in a year after stopping olaparib
5	10.1007/s12328-024-01992-1 (30)	Watanabe	2024	60	M	<i>BRCA1</i>	Locally advanced	GnP	PD	PR with FFX (6 cycles). Sent for conversion surgery. FFX as adjuvant chemotherapy in 6 months. No recurrence in 10 months after stopping FFX
6	10.1002/gcc.23222 (38)	Von Fritsch	2024	52	M	<i>BRAFV600E</i>	Peritoneal dissemination	mFFX	SD	SD with mFFX in 8 cycles. Stop by peripheral neurological disorders and fatigue. CR with dabrafenib/trametinib in 16 months
7	10.12998/wjcc.v11.i24.5823 (39)	Wang	2023	77	M	<i>ROS1-CENPW</i>	Liver metastasis	Dabrafenib/trametinib	PR	N/A
8	10.3389/fonc.2024.1357233 (24)	Wu	2024	45	F	High TMB	Locally advanced	Tripalimab	PR	N/A
9	10.3748/wjg.v28.i45.6421 (33)	Lee	2022	70	M	<i>BRCA2</i>	Liver metastasis	mFFX	PR	PR with mFFX in 15 cycles. Switch to olaparib due to peripheral neurological disorders. Maintained PR in 5 months
10	10.1002/cnr2.1648 (3)	Uemura	2022	67	M	N/A	Peritoneal dissemination	FFX	PR	PR with FFX in 19 months. Sent for conversion surgery. Adjuvant therapy with S1. No recurrence in 32 months after surgery
11	10.1002/ccr3.6718 (34)	Lelong	2022	38	M	<i>BRCA2</i>	Liver metastasis	FFX	PR	PR with FFX in 12 cycles. Switch to olaparib (maintain PR in 24 months)
12	10.1007/s12328-021-01571-8 (25)	Izumo	2022	65	M	N/A	Locally advanced (portal thrombus)	mFFX	PR	PR with mFFX in 14 cycles. Sent for conversion surgery. No recurrence in 33 months after surgery
13	10.1007/s12328-021-01518-z (2)	Maehira	2021	48	F	N/A	Liver metastasis after surgery	Cisplatin plus irinotecan	PR	PR with cisplatin plus IRI in 7 months. Switch to conversion surgery. No relapse in 33 months after surgery
14	10.6004/jnccn.2020.7641 (40)	Gupta	2021	81	M	<i>NTRK</i> fusion gene	Lymph-node relapse after surgery	GEM	PD	PD with GEM in 5 cycles. PD with GnP in 4 cycles
15	10.1200/PO.21.00400 (21)	Gaule	2022	62	M	Rearranged <i>ALK</i>	Liver metastasis after surgery	GnP	PD	PD with GnP in 3 cycles. PR with nal-IRI but PD in 6 months. PD with FOLFOX in 7 cycles. PR with Alectinib in 16 months
16	10.1177/0300891620980792 (41)	Xu	2020	68	M	PD-L1 positive plus high TMB	Lung, retroperitoneum, and lymph-node metastasis	GnP	SD	SD with GnP in 2cycles and skin rash. PD with SOX in 2 cycles. PR with SOX plus tripalimab
17	10.1159/000515267 (22)	Dreikhausen	2021	66	M	<i>BRCA2</i>	Liver metastasis	FFX	PR	PR with FFX. Exchange to FORFIRI by peripheral neurological disorders. Sent for conversion surgery. FORFIRI, GnP, and nal-IRI had PD for relapse in the liver. Olaparib was sent but the efficacy was not available
18	10.3389/fonc.2021.692480 (42)	Qin	2021	48	F	PD-L1 positive plus high TMB	Liver metastasis	Sintilimab plus lenvatinib	PR	PR with sintilimab plus lenvatinib in 21 months
19	10.1007/s12328-020-01146-z (26)	Villano	2020	71	M	N/A	Liver metastasis	FFX	PR	PR with FFX in 6 cycles. Sent for conversion surgery. No relapse in 6 months after surgery
20	10.1016/j.radcr.2019.11.005 (46)	Fontent	2019	56	M	N/A	Liver metastasis	FOLFOX	SD	PD with FOLFOX in 14 months. Sent for surgery
21	10.1080/15384047.2019.1595274 (18)	Kryklyva	2019	52	M	<i>BRCA2</i>	Metastasis for Liver, lung, peritoneum, and skin in 6 months after surgery	FFX	PR	PR with FFX in 24 months. Stopped FFX due to peripheral neurological disorders. Death in 3 months
22	10.2169/internalmedicine.0294-17 (47)	Yoshida	2018	79	F	N/A	Liver metastasis	S1	PR	PR with S1 in 3 years
23	10.4251/wjgo.v10.i4.103 (43)	Richard	2018	54	M	<i>EGFR</i>	Liver metastasis	FFX	PD	PD with FFX in 4 cycles. PD with GnP in 2 cycles. PR with panitumumab
24	10.1097/MD.00000000000013113 (35)	Li	2018	59	M	<i>BRCA2</i>	Retroperitoneum lymph node metastasis	FFX	PD	Radiation for lymph-node metastasis (not effective). Intra-tumoral brachytherapy by radioiodine-125 (not effective). PR with olaparib. Stopped olaparib due to severe complications. PD and death
25	N/A (48)	Kanematsu	2018	55	F	N/A	Liver and lung metastasis after surgery	GEM	PD	TAE (cisplatin plus 5-FU) plus microwave coagulation therapy and GEM
26	10.1097/MD.0000000000007904 (49)	Luo	2017	41	M	N/A	Locally advanced (portal thrombus)	FFX	SD	SD with FFX in 4 cycles. Survival in 19 months
27	10.1007/s12328-017-0785-5 (14)	Hashimoto	2017	67	M	N/A	–	mFFX	PR	PR with mFFX in 9 months
28	10.1159/000445867 (17)	Bechade	2016	59	N/A	N/A	Liver metastasis	GEM plus oxaliplatin	PR	PR with GEM plus oxaliplatin in 6 cycles. Radiofrequency ablation for liver tumor. No relapse in 6 months
29	10.1089/crpc.2016.0009 (23)	Jimbo	2016	56	M	N/A	Locally advanced (CA)	FFX	SD	SD with FFX in 3 cycles. PR with FOLFOX-6 in 6 cycles. Sent for conversion surgery
30	10.1080/17843286.2016.1168065 (36)	Naeyaert	2016	59	M	<i>BRCA2</i>	Liver metastasis	GEM	PD	PD with GEM. SD with carboplatin
31	N/A (27)	Toda	2016	52	M	N/A	Liver metastasis	GEM plus S1	PR	PR with GEM plus S1 in 5 cycles. Chemo-radiation therapy and surgery. No relapse in 59 months
32	10.1159/000441414 (50)	Ploquin	2015	50	M	N/A	Liver metastasis	GEM plus oxaliplatin	CR	CR with GEM plus oxaliplatin in 9 cycles. Stop chemotherapy by peripheral neurological disorders. No relapse in 14 years
33	10.1016/j.pan.2015.04.006 (51)	Callata-Carhuapoma	2015	36	F	N/A	Liver metastasis, peritoneal dissemination	Capecitabine plus temozolomide	PD	PD with capecitabine plus temozolomide in 2 cycles. SD with FFX in 9 months and PD in 11 months. PD with GnP
34	10.1016/j.pan.2015.09.006 (28)	Jaunch	2016	61	F	N/A	Liver metastasis	XEROX	PR	PR with XEROX in 11 cycles. Sent for conversion surgery. Relapse at liver in 30 months after surgery. PR with XEROX in 3 cycles. No relapse with capecitabine in 9 months
35	10.1055/s-0033-1356439 (52)	Schempf	2014	63	M	N/A	Liver metastasis	FFX	PR	PR with FFX in 10 cycles. Stop chemotherapy in 6 weeks. PR with FORFIRI in 7 months. Maintain PR after stopping FORFIRI in 6 months
36	10.1177/030089161309900230 (44)	Ang	2013	71	M	N/A	Liver metastasis	GEM plus cisplatin	PR	PR with GEM plus cisplatin in 6 months. Renal failure. PD with GEM plus oxaliplatin. PR with FORFIRI in a year. PR with HAI (floxuridine) plus IRI. IRI plus cetuximub in 1 year. PD with FORFIRI plus cetuximub
37	10.2169/internalmedicine.51.6536 (53)	Hiraoka	2012	25	F	N/A	Liver metastasis, peritoneal dissemination after excision of primary and hepatic lesion	GEM	PD	PD with GEM. Death in 2 months
38	10.3109/0284186X.2011.617388 (54)	Simon	2011	79	M	N/A	Liver metastasis	GEM	SD	PD with GEM in 2 months. PR with FOLFOX-4 in 12 cycles. Stop chemotherapy by peripheral neurological disorders and relapse. PR with FOLFOX in 12 cycles
39	N/A (29)	Yamamoto	2012	64	M	N/A	Peritoneal dissemination	S1	CR	CR with S1 in 5 cycles. Sent for conversion surgery. No relapse in 2 years
40	N/A (55)	Nishimizu	2011	64	M	N/A	Liver metastasis	GEM plus S1	PR	PR with GEM plus S1 in 6 cycles
41	N/A (56)	Morishima	2010	65	M	N/A	Liver metastasis after surgery	S1	CR	CR with S1 in 24 cycles. Excision of multiple right liver tumor. Relapse in 8 months after surgery
42	N/A (57)	Fujii	2010	59	M	N/A	Liver metastasis after surgery	GEM	PD	PD with GEM in 3 cycles. PD with S1 in 3 cycles. PR with HAI (cisplatin). Relapse in 20 months after HAI
43	10.1111/j.1365-2354.2008.01014.x (58)	Sorscher	2009	48	M	N/A	Liver metastasis after excision of primary and hepatic lesion	Paclitaxel	PD	PD with weekly paclitaxel in 6 cycles. PR with GEM plus 5-FU in 9 cycles
44	10.1186/1477-7819-7-22 (16)	Distler	2009	65	M	N/A	Locally advanced (portal vein)	5-FU	PR	PR with 5-FU in a year. Sent for conversion surgery. No relapse in 18 months after surgery
45	10.1093/jjco/hyp085 (59)	Seki	2009	48	M	N/A	Liver metastasis after excision of primary and hepatic lesion	GEM	SD	SD with GEM in 6months. Excision of new liver metastatic lesion. Relapse in remnant liver in 7 months. PD with S1
46	10.1093/jjco/hyp085 (59)	Seki	2009	67	M	N/A	Liver, bone, and lymph-nodes metastasis	GEM	PD	N/A
47	10.1093/jjco/hyp085 (59)	Seki	2009	67	M	N/A	Locally advanced (SMA)	GEM	PD	PD with GEM in 2 cycles. PR with S1 in 4 cycles. PD with additional S1 in 4 cycles
48	10.1093/jjco/hyp085 (59)	Seki	2009	61	F	N/A	Locally advanced (SMA)	GEM	SD	SD with GEM in 6 cycles. New lesion in liver. PD with S1
49	N/A (20)	Antonie	2007	44	F	N/A	Liver metastasis	GEM plus irinotecan	SD	SD with GEM plus IRI in 7 cycles. SD with GEM plus oxaliplatin in 16 cycles. PD with docetaxel plus capecitabine (6 cycles). PD with FORFIRI. PD with GEM plus erlotinib
50	10.1159/000107397 (19)	Harten	2007	77	M	N/A	Liver metastasis	GEM plus mitomycin	PR	PR with GEM plus mitomycin in 3 months and additional GEM in 3 months
51	N/A (60)	Mori	2004	33	M	N/A	Locally advanced (CA, SMA)	Cisplatin plus 5-FU	SD	SD with cisplatin plus 5-FU. PR with HAI (cisplatin plus 5-FU)
52	10.1159/000077316 (61)	Beltraminelli	2004	60	M	N/A	Liver metastasis	GEM	PD	PD with GEM in 7 cycles
53	10.1385/IJGC.34:2-3:067 (45)	Pimenta	2003	43	F	N/A	Peritoneal dissemination	GEM	SD	SD with GEM in 7 cycles. PD with capecitabine. PD with raltitrexed plus oxaliplatin. PD with IRI. PR with paclitaxel in 4 months. PD with imatinib mesylate

CA, celiac artery; CR, complete response; F, female; FFX, FORFIRINOX; GEM, gemcitabine; GnP, gemcitabine plus nab-paclitaxel; HAI, hepatic arterial infusion; IRI, irinotecan; M, male; mFFX, modified FORFIRINOX; MSIXEROX, capecitabine and oxaliplatin; N/A, not available; PD, progressive disease; PR, partial response; S1, tegafur/gimeracil/oteracil; SD, stable disease; SMA, superior mesenteric artery; TAE, transcatheter arterial embolization.

References

46. Fontenot J, Spieler B, Hudson C, et al. Corrigendum to "Pancreatic acinar cell carcinoma-literature review and case report of a 56-year-old man presenting with abdominal pain" [Radiol Case Rep 15 (2020) 39-43]. Radiol Case Rep 2019;15:306-7. Erratum for: Radiol Case Rep 2019;15:39-43.
47. Yoshida N, Kanno A, Masamune A, et al. Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy. Intern Med 2018;57:3529-35.
48. Kanematsu K, Suematsu Y, Yamagishi S, et al. Prolonged Survival Achieved with Surgical Resection and Multidisciplinary Therapy for Acinar Cell Carcinoma of the Pancreas with Liver Metastases. Gan To Kagaku Ryoho 2018;45:312-4.
49. Luo Y, Hu G, Ma Y, et al. Acinar cell carcinoma of the pancreas presenting as diffuse pancreatic enlargement: Two case reports and literature review. Medicine (Baltimore) 2017;96:e7904.
50. Ploquin A, Baldini C, Vuagnat P, et al. Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma. Case Rep Oncol 2015;8:447-50.
51. Callata-Carhuapoma HR, Pato Cour E, Garcia-Paredes B, et al. Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthrititis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. Pancreatol 2015;15:440-4.
52. Schempf U, Sipos B, König C, et al. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report. Z Gastroenterol 2014;52:200-3.
53. Hiraoka A, Nakahara H, Kawasaki H, et al. Huge pancreatic acinar cell carcinoma with high levels of AFP and fucosylated AFP (AFP-L3). Intern Med 2012;51:1341-9.
54. Simon M, Bioulac-Sage P, Trillaud H, et al. FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature. Acta Oncol 2012;51:403-5.
55. Nishimizu T, Minemura M, Kajiura S, et al. A case of pancreatic acinar cell carcinoma with a giant liver metastasis successfully treated with combination of gemcitabine and peroral S-1. Gan To Kagaku Ryoho 2011;38:309-12.
56. Morishima K, Hyodo M, Nihei Y, et al. A case of acinar cell carcinoma of pancreas with liver metastases treated effectively by S-1. Gan To Kagaku Ryoho 2010;37:127-9.
57. Fujii M, Sato H, Ogasawara T, et al. A case of liver metastasis of pancreatic acinar cell carcinoma treated with S-1 and intra-arterial CDDP combination therapy. Gan To Kagaku Ryoho 2010;37:1987-90.
58. Sorscher SM. Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report. Eur J Cancer Care (Engl) 2009;18:318-9.
59. Seki Y, Okusaka T, Ikeda M, et al. Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. Jpn J Clin Oncol 2009;39:751-5.
60. Mori S, Kondoh S, Ryozaawa S, et al. A case of AFP producing pancreatic acinar cell carcinoma diagnosed by EUS FNA and treated by intraarterial injection chemotherapy. Nihon Shokakibyo Gakkai Zasshi 2004;101:177-82.
61. Beltraminelli HS, Buechner SA, Häusermann P. Pancreatic panniculitis in a patient with an acinar cell cystadenocarcinoma of the pancreas. Dermatology 2004;208:265-7.